Patient has been administering latanoprost eye drops in affected eye(s) for at least 12 weeks prior to study

Patient must have at least partially responded to latanoprost and requiring further IOP lowering eye drops

Diagnosis of chronic angle-closure glaucoma

Patients using COMBIGAN® in the past must not have been discontinued due to adverse events or lack of efficacy.

Study of Brimonidine and Timolol Ophthalmic Solution With Latanoprost Compared With Latanoprost in Glaucoma Patients